ADPT
Adaptive Biotechnologies Corporation·Healthcare
12.79
4.552%(−0.61)
Market ClosedLast Updated: — ET
52W L: $6.7852W H: $20.76
ADPT NEWS
fool.com
3d ago
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
The President and COO of Adaptive Biotechnologies Corporation reported the sale of 38,120 shares for about $554,000, based on a weighted average transaction price of $14.53 per share across April 1–2, 2026. This sale represented 7.85% of Rubinstein's direct Common Stock holdings, reducing her direct position to 447,202 shares post-transaction.
defenseworld.net
6d ago
JPMorgan Chase & Co. Sells 799,246 Shares of Adaptive Biotechnologies Corporation $ADPT
JPMorgan Chase and Co. lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 77.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 235,668 shares of the company's stock after selling 799,246 shares during the quarter. JPMorgan Chase and Co.
fool.com
Mar 30
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look
81,342 shares were sold for a total value of ~$1.21 million across multiple transactions from March 6 to March 10, 2026. The sale represented 11.22% of Rubinstein's direct holdings, reducing her direct ownership to 643,471 shares post-transaction.
fool.com
Mar 26
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year
An executive at Adaptive Biotechnologies reported the sale of 179,703 shares for about $2.37 million, based on a weighted average price of around $13.21 per share during March 11–13, 2026. This sale was executed directly and arose from the exercise and immediate sale of option-derived Common Stock; no indirect (e.g.
fool.com
Mar 26
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price
Francis Lo, Chief People Officer at Adaptive Biotechnologies (ADPT +0.00%), reported the sale of a combined 68,667 shares of common stock across two transactions in early March 2026, as disclosed in a pair of SEC Form 4 filings.
zacks.com
Mar 16
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
